argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer.
Flawless balance sheet and slightly overvalued.
Share Price & News
How has argenx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ARGX's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ARGX exceeded the Belgian Biotechs industry which returned 53.4% over the past year.
Return vs Market: ARGX exceeded the Belgian Market which returned -20.7% over the past year.
Price Volatility Vs. Market
How volatile is argenx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StNews Flash: Analysts Just Made A Meaningful Upgrade To Their argenx SE (EBR:ARGX) Forecasts
1 month ago | Simply Wall StIs argenx SE's (EBR:ARGX) CEO Overpaid Relative To Its Peers?
3 months ago | Simply Wall Stargenx's (EBR:ARGX) Incredible 1688% Share Price Run Shows What Is Possible With Stocks
Is argenx undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ARGX (€195.9) is trading below our estimate of fair value (€380.79)
Significantly Below Fair Value: ARGX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ARGX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ARGX is unprofitable, so we can't compare its PE Ratio to the Belgian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARGX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARGX is overvalued based on its PB Ratio (8x) compared to the BE Biotechs industry average (3.4x).
How is argenx forecast to perform in the next 1 to 3 years based on estimates from 14 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARGX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARGX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARGX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARGX's revenue (62.4% per year) is forecast to grow faster than the Belgian market (2.5% per year).
High Growth Revenue: ARGX's revenue (62.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARGX is forecast to be unprofitable in 3 years.
How has argenx performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARGX is currently unprofitable.
Growing Profit Margin: ARGX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARGX is unprofitable, and losses have increased over the past 5 years at a rate of -57.1% per year.
Accelerating Growth: Unable to compare ARGX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARGX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.5%).
Return on Equity
High ROE: ARGX has a negative Return on Equity (-23.77%), as it is currently unprofitable.
How is argenx's financial position?
Financial Position Analysis
Short Term Liabilities: ARGX's short term assets (€1.4B) exceed its short term liabilities (€160.0M).
Long Term Liabilities: ARGX's short term assets (€1.4B) exceed its long term liabilities (€222.6M).
Debt to Equity History and Analysis
Debt Level: ARGX is debt free.
Reducing Debt: ARGX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ARGX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ARGX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 31.2% per year.
What is argenx's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARGX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARGX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARGX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARGX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARGX's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tim Van Hauwermeiren (47yo)
Mr. Tim Van Hauwermeiren, MSc, EMBA, has been the Chief Executive Officer and Executive Director at argenx SE since July 2008 and July 9, 2014 respectively. Mr. Van Hauwermeiren co-founded Argenx SE in 200 ...
CEO Compensation Analysis
Compensation vs Market: Tim's total compensation ($USD6.76M) is above average for companies of similar size in the Belgian market ($USD2.42M).
Compensation vs Earnings: Tim's compensation has increased whilst the company is unprofitable.
|CEO & Executive Director||11.83yrs||€6.15m||no data|
|Chief Financial Officer||6.08yrs||no data||no data|
|Chief Operating Officer||2.08yrs||no data||no data|
|Chief Scientific Officer||11.83yrs||no data||0.13% €11.9m|
|General Counsel||3.08yrs||no data||no data|
|Vice President of Corporate Development & Strategy||0.92yr||no data||no data|
|Chief Medical Officer||0.83yr||no data||no data|
|Director Corporate Communications & Investor Relations (EU)||no data||no data||no data|
|Global Head of Human Resources||1.42yrs||no data||no data|
|Global Head of Quality Assurance||0.33yr||no data||no data|
Experienced Management: ARGX's management team is considered experienced (2.1 years average tenure).
|CEO & Executive Director||11.83yrs||€6.15m||no data|
|Independent Non-Executive Director||5yrs||€709.67k||no data|
|Independent Chairman of the Board||5.83yrs||€734.67k||no data|
|Independent Vice-Chairperson||no data||€712.17k||0.071% €6.5m|
|Independent Non-Executive Director||3.08yrs||€707.17k||no data|
|Independent Non-Executive Director||4.08yrs||€699.67k||no data|
|Independent Non-Executive Director||5.83yrs||€707.17k||no data|
|Independent Non-Executive Director||2yrs||€707.17k||no data|
Experienced Board: ARGX's board of directors are considered experienced (5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ARGX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.
argenx SE's company bio, employee growth, exchange listings and data sources
- Name: argenx SE
- Ticker: ARGX
- Exchange: ENXTBR
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €9.100b
- Shares outstanding: 46.45m
- Website: https://www.argenx.com
Number of Employees
- argenx SE
- Willemstraat 5
- 4811 AH
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ARGX||ENXTBR (Euronext Brussels)||Yes||Ordinary Shares||BE||EUR||Jul 2014|
|0QW0||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jul 2014|
|ARGN.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jul 2014|
|ARGXB||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jul 2014|
|1AE||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jul 2014|
|ARGX||NasdaqGS (Nasdaq Global Select)||American Depository Receipts||US||USD||May 2017|
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer indications; and preclinical products, including ARGX-117 with therapeutic potential in both orphan and large autoimmune inflammatory diseases in and ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation and ARGX-115 for cancer immunotherapy, which are in Phase 1 clinical stages; and ARGX-116 for the treatment of dyslipidemia and ARGX-114 for treating fibrosis, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/29 14:26|
|End of Day Share Price||2020/05/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.